Table 2.

Summary of treatment-related adverse events

	Preoperative chemotherapy (n = 45)		Postoperative chemotherapy (n = 31)
	Any grade	≥ Grade 3	Step 1 (n = 11)		Step 2 (n = 20)
			Any grade	≥ Grade 3	Any grade	≥ Grade 3
Hematological
Platelet count decreased	17 (37.8)	0 (0.0)	1 (9.1)	0 (0.0)	9 (45.0)	1 (5.0)
Anaemia	7 (15.6)	1 (2.2)	1 (9.1)	0 (0.0)	2(10.0)	1 (5.0)
Neutrophil count decreased	6 (13.3)	4 (8.9)	3 (27.3)	1 (9.1)	6 (30.0)	2 (10.0)
WBC count decreased	4 (8.9)	1 (2.2)	2 (18.2)	0 (0.0)	3 (15.0)	0 (0.0)
Non-hematological
Peripheral sensory neuropathy	32 (71.1)	0 (0.0)	0 (0.0)	0 (0.0)	9 (45.0)	0 (0.0)
Diarrhoea	27 (60.0)	8 (17.8)	4 (36.4)	1 (9.1)	12 (60.0)	0 (0.0)
Nausea	25 (55.6)	1 (2.2)	2 (18.2)	0 (0.0)	9 (45.0)	0 (0.0)
Decreased appetite	20 (44.4)	2 (4.4)	5 (45.5)	1 (9.1)	10 (50.0)	1 (5.0)
Stomatitis	20 (44.4)	2 (4.4)	1 (9.1)	0 (0.0)	4 (20.0)	0 (0.0)
Constipation	20 (44.4)	0 (0.0)	1 (9.1)	0 (0.0)	1 (5.0)	0 (0.0)
AST increased	13 (28.9)	0 (0.0)	2 (18.2)	0 (0.0)	6 (30.0)	0 (0.0)
ALT increased	12 (26.7)	0 (0.0)	2 (18.2)	0 (0.0)	5 (25.0)	0 (0.0)
Fatigue	9 (20.0)	1 (2.2)	2 (18.2)	0 (0.0)	2 (10.0)	0 (0.0)
Pyrexia	9 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (10.0)	0 (0.0)
Duodenal perforation	1 (2.2)	1 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypokalaemia	1 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	4 (20.0)	3 (15.0)
Palmar-plantar erythrodysaesthesia syndrome	0 (0.0)	0 (0.0)	4 (36.4)	0 (0.0)	1 (5.0)	0 (0.0)

Data are n (%). Adverse events that commonly occur are shown. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (version 4.03)

WBC white blood cell, AST aspartate aminotransferase, ALT alanine aminotransferase